RUNNING TITLE Pharmaconutrition and gastrointestinal surgery
INTRODUCTION
Nutrition provision is recognized to be an important aspect in the perioperative management of elective gastrointestinal surgery patients, and the timely provision of nutrition has been associated with improved postoperative outcomes 1, 2 . The benefits of nutritional provision in surgical patients are traditionally thought to arise from the provision of macronutrients such as calories for energy and protein for wound healing, and to reduce the impact of catabolism in the postoperative period. However, it has been theorized that due to the complex inflammatory, immune and oxidative stress that is experienced postoperatively, providing specific nutrients in supraphysiological doses may provide vital substrates that serve to modulate these immune and metabolic responses and thus improve clinical outcomes 3 . In view of this, during the early 1990s new nutrition support formulas emerged containing higher quantities of arginine, with or without glutamine, omega-3 fatty acids, and nucleotides 3 . These products have been commonly referred to as 'immunonutrition', 'immune-enhancing diets', and more recently as 'pharmaconutrition' in recognition of their intended pharmaceutical-like action rather than purely as nutrient provision 3 .
In an elective surgical population, the use of pharmaconutrition has been reported to reduce postoperative infective complications and LOS, without adversely affecting mortality described in medical and trauma subgroups of a critically ill population [4] [5] [6] [7] [8] [9] [10] . The results of individual studies have been conflicting [11] [12] [13] [14] [15] , however the use of these products gain increasing acceptance following their incorporation into practice guidelines 16, 17 . Seven metaanalyses on this topic have been conducted on surgical patients [18] [19] [20] [21] or with surgical patients as a subgroup analysis of a critical care population [22] [23] [24] , however there are limitations to applying the outcomes of these meta-analyses to practice due to the inclusion of studies utilizing non-equivalent control groups, inclusion of diverse surgical populations, and the failure to account for practical differences between the studies (i.e. administration protocols of pharmaconutrition).
The objective of the current work is to further explore the literature describing the postoperative outcomes from RCTs comparing the timing of provision of arginine-dominant pharmaconutrition formulations with standard products in an elective gastrointestinal surgery population. The timing of pharmaconutrition provision is considered of the utmost importance as this information is necessary to guide clinical practice and institutional policy. The current work differs from previous meta-analyses through the emphasis on timing of pharmaconutrition provision, use of stricter inclusion criteria to reduce heterogeneity in the results obtained, and by including the latest available publications.
MATERIALS AND METHODS

Inclusion and Exclusion Criteria
Studies comparing the provision of arginine-dominant (>9g Arg/L) pharmaconutritional formulations with or without other immune-modulating nutrients to those of standard nutritional composition were reviewed. Only RCTs with primary comparisons between the different nutritional formulations were considered for inclusion. For inclusion, studies must also have been conducted in adult (>18 years) elective gastrointestinal surgical patients, and have reported on clinically relevant outcomes pertaining to the postoperative period. Outcomes assessed were those considered to exert influence over practical aspects of surgical practice and institutional policy decisions. All studies reporting on outcomes of this nature were considered and final analyses were run on outcome variables where numbers were sufficient to allow statistical analysis.
Additional exclusion criteria included studies that investigated the effect of parenteral provision supplemented with pharmaconutrients, and duplicate publications.
Search Strategies and Data Collection
Electronic databases (Medline, Pubmed, EMBASE, CINAHL, Cochrane Register of Systematic Reviews, Science Citation Index) were cross-searched for RCTs published between 1980 and 2011, using search terms customized to each search engine in an attempt to detect published papers meeting the inclusion criteria. Limits were set to RCTs and adult patients to reflect the inclusion criteria. Search strategies utilized included (IMMUNONUTRITON and SURGERY), (IMMUN* and NUTRITION), (PHARMACONUTRITION), (ARGININE or OMEGA-3 or RNA or NUCLEOTIDE and SURGERY). Reference lists of reviews and existing meta-analyses were hand searched for further appropriate citations. Companies that produce pharmaconutrition products and experts in the field were contacted for information about unpublished studies. Where necessary, authors were contacted by e-mail (and follow-up letter by post where a response to a second e-mail was not received) for clarification or additional information.
The data were prepared in accordance with the Preferred Reporting of Systematic Reviews and Meta-Analyses (PRISMA) statement 25 . Data extraction and critical appraisal of identified studies were carried out by two authors (EO and MAM) for compliance with inclusion criteria. The authors were not blinded to the source of the document or authorship for the purpose of data extraction. The data were compared and discrepancies were addressed with discussion until consensus was achieved.
Evaluation of methodological quality of identified studies was conducted using the Jadad scoring system which provides a numerical quality score based on the reporting of randomization, blinding and reporting of withdrawals 26 .
Statistical Analysis
Meta-analyses were performed using odds ratios (ORs) for binary outcomes and weighted mean differences (WMDs) for continuous outcome measures. A slightly amended estimator of OR was used to avoid the computation of reciprocal of zeros among observed values in the calculation of the original OR 27 . Random effects models, developed by using the inverse variance weighted method approach 28 , were used to combine the data. Heterogeneity among the study measures was assessed using the Q statistic [28] [29] [30] and I 2 index 31, 32 . Sensitivity analyses were conducted by removing studies that utilized experimental formulations with considerable differences in their product formulation to assess their influence on the results obtained.
Funnel plots were synthesized in order to determine the presence of publication bias in the meta-analysis. Standard error was plotted against the treatment effects (Log OR for the dichotomous and WMD for continuous variables respectively) 28, 33, 34 to allow 95% confidence interval limits to be displayed. All estimates were obtained using computer programs written in R
35
. All plots were obtained using the 'rmeta' package 36 .
A significance level of 5% ( =0.05) was applied to tests of hypotheses.
RESULTS
Included studies
Cross searching of electronic databases yielded a total of 211 abstracts and hand searches of reference lists provided a further 16 citations. After exclusion of 136 duplicate citations, 91 unique citations of potential relevance were retrieved for review. The process by which these were excluded from inclusion is described in Figure 1 . Two potentially relevant studies 37, 38 were unable to be assessed due to lack of access to the non-English language journals in which they were published. While a further potentially relevant unpublished study ('Sydney') was identified through a citation search of a previous published meta-analysis 18 , attempts to contact authors and the company manufacturing the product did not yield any additional information; therefore the study could not be assessed for inclusion. Correspondence with the companies producing commercially available pharmaconutrition products did not yield additional unpublished studies, however the plans for an upcoming RCT were obtained through correspondence with an author of the Waitzberg et al 18 meta-analysis.
The twenty studies that met the inclusion criteria are described in Tables 1 to 4 , however due to multiple arms of single studies independently meeting the inclusion criteria in one study 12 there were twenty-one individual sets of data analyzed. For eligible studies that incorporated multiple intervention arms in their study design, only those that utilized the enteral route were included in the analysis. Pooled results yielded 2005 patients (n=1010 pharmaconutrition; n=995 control) from studies published between 1988 and 2011. Studies were categorized according to the timing of pharmaconutrition provision: four studies, yielding five sets of data, provided preoperative interventions (pharmaconutrition provided five to seven days preoperatively as oral supplement), fourteen studies described postoperative interventions (pharmaconutrition product commenced via jejunal feeding tube on Postoperative Day (POD) 1 or 2, used to meet a defined nutritional goal until POD7 or when oral intake was established); and two studies provided perioperative interventions (providing both pre-and postoperative provision of pharmaconutrition as described above).
The included studies collectively demonstrate moderate methodological quality according to the Jadad score with an average score of 3.1 (out of five), with a range of one to five. Fourteen studies reported on withdrawals 4, 5, 9, [11] [12] [13] [14] [15] [39] [40] [41] [42] [43] [44] , thirteen described an appropriate method of randomization 4-7, 9, 13, 14, 39-42, 45, 46 , and eight studies reported utilizing blinding 5, 9, 12, 42, 44, 47 . One study was not included in the eight that reported using a blinded method, as although it states it was a double-blind methodology in the title, this was not referred to throughout the article 40 . Jadad scores are reported in Tables 2 to 4.
All but seventeen patients (fourteen from Jiang et al 43 , two from Sodergren 45 and one from
Daly et al 47 representing <1% of the total patients analyzed) received elective surgery for the curative management of gastrointestinal malignancies (see Table 4 ). Twelve studies reported on the rates of malnutrition within their study population 4-7, 9, 12-15, 40, 41, 47 : Rates varied greatly, ranging from 9% to 100% with an average of about 40%. Malnutrition was defined as ≥10% body weight loss in most studies.
The nutritional composition products utilized in the included studies are summarized in Tables 5 and 6 . All but three studies used commercially available pharmaconutrition products of similar composition (that is, Arginine 9-12g/L, with omega-3 fatty acids and nucleotides): Impact ® or Oral Impact ® account for 65% of the studied products. The experimental products used by McCarter et al 12 and Daly et al 47 were of significantly different composition (higher arginine (26g/L) content, with or without glutamine or omega-3 fatty acids). The Sodergren et al 45 study product was reported to be a prototype of Intestamin ® that contains arginine, glutamine, omega-3 fatty acids, and micronutrients, however the exact composition of the product could not be ascertained due to it being subject to 'commercial in confidence' conditions (personal communication). The authors' [EO and MAM] interpretation of the nature of the feeding regimen for the prototype product suggests a composition more similar to the existing pharmaconutrition products used in a surgical population than to the commercially available Intestamin ® product 48 , it was therefore included in the meta-analysis but omitted for sensitivity analyses.
Thirteen of the twenty studies included stated they received support from the companies that produce the products being studied 4-7, 9, 11, 12, 39, 41, 42, 44, 45, 47 . Support was most commonly received through the provision of pharmaconutrition products, and occasionally though direct financial support. Other studies are unclear about the nature of company involvement 14, 15, 43, 46, 49 , and only two studies deny any conflict of interest or financial support 13, 40 .
Clinical Outcomes
Sufficient data were available for the analysis for six clinically relevant outcomes: in-hospital mortality; infective complications; anastomotic dehiscence; non-infectious complications; LOS; and gastrointestinal tolerance. Omission of studies 45, 47 using non-commercially available products did not alter the outcomes obtained in the sensitivity analyses (data not presented).
Heterogeneity
In general there was a high degree of accord between the outcomes in the included studies, with significant heterogeneity only detected in LOS. The latter was consistent across all timings of pharmaconutrition administration for this outcome.
Publication Bias
Funnel plots demonstrate symmetry and thus suggest the absence of publication bias for all outcomes except LOS. (Figure 6 ).
DISCUSSION
This meta-analysis both confirms previous findings regarding arginine-dominant pharmaconutrition and provides further insight into the effects of its use. Firstly it continues to show no adverse effect on postoperative mortality in elective gastrointestinal surgical populations. It also supports the commonly accepted benefits of arginine-dominant pharmaconutrition with relation to reductions in postoperative infective complications, however these benefits were only seen in peri-and postoperative pharmaconutrition administration in the current work. Similarly, reductions in LOS were noted in peri-and postoperative administration, however heterogeneity evidenced by a high I 2 index and publication bias present in this data makes it difficult to draw concrete conclusions on this parameter.
Distinct differences in the attributed benefits of pharmaconutrition and the timing of its administration is an important finding of this meta-analysis. Previous meta-analyses performing a priori analyses on timing of pharmaconutrition report benefit irrespective of when in the clinical course it is provided 19, 20 . One notable exception is that preoperative pharmaconutrition was not shown to reduce LOS by Cerantola et al 20 . The current work demonstrates no benefit from the provision of preoperative pharmaconutrition across any of the outcomes assessed. A possible explanation for this is the stricter inclusion criteria applied to minimise heterogeneity. Thus the results reported may be a truer indication of the effect of preoperative pharmaconutrition in this surgical population. The pharmacokinetics of pharmaconutrients may assist in understanding this finding. Serum arginine levels have been shown to significantly increase following seven days of preoperative 12, 50 and postoperative administration 41, 51 . Sustained elevated serum levels have been demonstrated at POD8 with perioperative administration 50 . However no study appears to have investigated the postoperative serum levels of patients receiving preoperative pharmaconutrients as a standalone intervention. It is therefore conceivable that the cessation of pharmaconutrition on the day of surgery may result in sub-therapeutic or declining levels of circulating pharmaconutrients within the postoperative period when their action may be most valuable. Beta-error (false negative) may also play a part in the findings reported in this and/or previous meta-analyses given the small number of studies investigating preoperative pharmaconutrition interventions.
The current work further suggests that pharmaconutrition may provide additional benefits in terms of reduction of anastomotic dehiscence and non-infective complications in perioperative and postoperative administration respectively -these phenomena have not previously been reported in association with arginine-dominant pharmaconutrition. Reduced non-infectious complications in postoperative pharmaconutrition provision may potentially be explained by the higher caloric and/or nitrogen content of many of the pharmaconutrition formulations when compared to the control formulations. Six of the fourteen studies (42%) included in the postoperative meta-analysis use intervention products that contain between 20 and 46% more protein 11, 14, 40, 43, 47, 49 and/or up to 600kcal (20%) more energy 14 than the control formulations. In a gastrointestinal surgical population with a high prevalence of malnutrition, the higher overall nutritional provision may be enough to account for this unexpected finding given that malnourished patients experience more profound improvements in clinical outcomes attributable to nutritional provision than their wellnourished counterparts 52 . This explanation, however, does not adequately explain the reduced anastomotic dehiscence reported with the perioperative administration of pharmaconutrition as these used comparable products for both arms of their studies. As leukocytosis is recognised as a risk factor for anastomotic dehiscence 53 it seems plausible that the reduction in infective complications associated with pharmaconutrition may provide additional protection in the surgical anastomosis through this mechanism. However given the small number of perioperative studies analysed (k=2), beta-error may also be a plausible explanation for this finding.
Although seven meta-analyses on this topic already exist, there are limitations contained within these that justify a further meta-analysis. surgery with an otherwise largely gastrointestinal surgery population, and included studies that utilised non-equivalent control groups such as intravenous fluids or crystalloids, or nilby-mouth. The heterogeneity introduced through these inclusions, the exclusion of studies conducted using other similarly composed commercial products, and the suggestion that this meta-analysis has been funded by Novartis result in the need to interpret the outcomes of this analysis with caution.
Zheng et al 21 restricts inclusion criteria to gastrointestinal surgery but makes no attempt to control for the differences within the administration of pharmaconutrition between studies. Furthermore, an additional ten studies have been identified as being published since 2006 that were not available to be included in this study.
Marik and Zaloga 19 compared the effect of arginine and/or omega-3 containing pharmaconutrition products with standard formulations, and included a priori analyses on differing compositions and timing of pharmaconutrition. Their results are difficult to apply to practice, however, due to the heterogeneous surgical populations included (head and neck, cardiac, gastrointestinal) and the significant methodological flaw of performing meta-analysis statistics in instances where only one study met the inclusion criteria 54 .
The most recent meta-analysis was published by Cerantola et al 20 in 2011. This paper incorporated recently published studies on an exclusively gastrointestinal surgical population, addressed the timing of pharmaconutrition provision through performing subgroup analyses, and is the first meta-analysis on this topic to comply with PRISMA reporting guidelines. However, it also includes studies that use non-equivalent control groups 7, 8, 10, 55 : This may produce outcomes that appear to favour pharmaconutrition independent of the role of immune-enhancing components.
For these reasons the current work has attempted to contribute to the literature on this topic through producing a meta-analysis that utilises stricter inclusion criteria with regards to the control group (as far as the literature allows), and to exclusively analyse studies according to the timing of pharmaconutrition delivery. We believe this issue is of vital importance to guide the translation of research to clinical practice.
This meta-analysis is not without its limitations. Firstly, there are variations in the composition of included pharmaconutrition products that may confound the results obtained. The decision to allow inclusion of studies using products containing arginine +/-other pharmaconutrients was based on consideration that arginine has been the most consistently utilized pharmaconutrient in elective gastrointestinal surgical populations, and remains the consistent ingredient that links commercial and experimental formulas in this genre of products. Other pharmaconutrients included in the commercially available formulas have limited clinical evidence of individual benefit when provided enterally in this patient group in the absence of arginine. On this basis we argue that there is clinical relevance to classifying the intervention products as 'arginine-dominant'.
Secondly, while all studies described the nutritional goals for their patients throughout the study period, few quantified the amount of nutrition actually received. We have therefore been forced to assume that nutrition goals were consistently met unless otherwise stated. This has obvious implications for the conclusions drawn, as reduced nutritional provision for reasons such as feed intolerance, non-compliance with oral supplements, tube-related complications or protocol deviations may have reduced the provision of nutrients and therefore may confound the results obtained. This aspect of reporting trials on pharmaconutrition need to be addressed in future studies on this topic.
Thirdly, the majority of the pharmaconutrition studies have been funded at least in part by the companies that manufacture the products being investigated. This is of concern as funding bias is recognised for its potential to influence the results in favour of the product being investigated in pharmaceutical studies 56, 57 . As meta-analysis is known to amplify biases included in the individual studies, the concern that funding bias may be present and has the potential to exaggerate the beneficial effects of pharmaconutrition should not be overlooked: This is true of both the current work and the existing meta-analyses on this topic. This is of particular concern given the increasing acceptance that pharmaconutrition has found in clinical practice through its incorporation into clinical guidelines 16, 17 .
Interestingly, discussion of this aspect of pharmaconutrition is notably absent from the literature at the present time.
Closely tied to concerns regarding funding bias is the frequent use of non-comparable control groups: this is a commonly observed trend in pharmaceutically funded studies that are subsequently shown to favour the intervention product 57 . Significantly different protein contents between some of the intervention and control products were noted in several of the included studies. One such example is the Klek et al 14 study that uses Peptisorb® [Nutricia Ltd, Poland] (40g protein/L; 1kcal/mL) as the control product against Stresson® [Nutricia Ltd, Poland] (75g protein/L; 1.25kcal/mL). While the lack of reporting of received nutrition make the significance of these differences on the current work impossible to evaluate, even in studies that utilise individualized nutritional goals based on caloric targets, such marked differences in formulations may ultimately undermine the controlled nature of individual studies due to the lack of appropriate control group.
We made multiple attempts to contact authors for additional information or clarification of data within their publications but with disappointing response rates. In the absence of response from the group from Milan, Italy who published many of the papers on this topic in the mid-1990s and early 2000s, we excluded any of their studies we strongly suspected of representing multiple reports on the same patients [58] [59] [60] . however adequate data to assess them for inclusion were unavailable despite our best efforts to obtain these. This unfortunate situation suggests the presence of location bias within the present work.
Finally, this meta-analysis retains the unavoidable heterogeneity introduced by the failure of the included studies to report the results of individual surgical procedures. This is significant as the complications likely to occur after procedures performed at various locations along the gastrointestinal tract vary greatly, and as such the indiscriminate grouping of these may confound the complications reported, and thus the effect attributed to the pharmaconutrition interventions provided.
This meta-analysis has highlighted areas for future research. As described above, the nutritional aspects of studies on this topic including the reporting of nutritional consumption in both groups throughout the study period, and the need for careful selection of control formulas are potential confounders in many of the existing published studies. Dietitians are largely absent from the authorship of the studies to date, and it seems likely that a more multidisciplinary approach to the research in this area is necessary, and is likely to alleviate these oversights in future studies. Secondly, convincing data supporting significant economic benefit related to the use of pharmaconutrition over standard nutrition products remains scarce in the literature. A strong body of evidence supporting the cost-benefit of pharmaconutrition is going to be increasingly vital to justify its continued use in healthcare environments that are increasing subjected to financial scrutiny in these difficult economic times.
CONCLUSIONS:
While this meta-analysis lends support to the acknowledged beneficial effects of pharmaconutrition in the management of elective gastrointestinal surgical patients, it highlights the importance of timing of administration as a clinical consideration. Contrary to previous findings, preoperative pharmaconutrition failed to deliver any benefit over standard formulations when used as a standalone intervention, and the accepted benefits of pharmaconutrition (reduction in infectious complications and LOS) were only reported in peri-and postoperative administration, and limitations in the LOS data obscure the conclusions we can draw on this outcome. It also suggests previously unreported benefits of pharmaconutrition with respect to reduced non-infective complications and anastomotic dehiscence in postoperative and perioperative administration respectively. Better quality, multi-disciplinary intervention and cost-benefit studies are required to further clarify the remaining questions on this topic. 
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